PremiumThe FlyMyriad Genetics price target lowered to $11 from $13 at BofA Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes Myriad Genetics Reports Strong Growth Amid Challenges PremiumRatingsHold Rating on Myriad Genetics Amid Leadership Transition and Adjusted Revenue Expectations Myriad Genetics Announces CEO Transition in 2025 Myriad Genetics CEO Paul Diaz to depart, Sam Raha to succeed PremiumPre-EarningsMYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings? Craig-Hallum bulish on Myriad Genetics, initiates with a Buy Myriad Genetics initiated with a Buy at Craig-Hallum 
